对抗卡巴尼姆耐药的Acinetobacter baumannii感染的治疗方法
Alina Iovleva1, Vance G Fowler2,3, Yohei Doi4,5
1Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
耐碳胺的 Acinetobacter baumannii 每年造成超过30万人的死亡. 本综述探讨了对这种具有挑战性的病原体的治疗策略,强调了新兴疗法和临床验证的需要.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐卡巴胺的宝曼尼菌 (Acinetobacter baumannii,简称CRAB) 是全球严重的健康威胁,导致严重的死亡率和发病率.
- 对现有抗生素的高耐药率使治疗复杂化,没有关于最佳策略的建立全球共识.
- 缺乏大规模的受控研究和治疗方案的异质性阻碍了对CRAB感染的有效管理.
研究的目的:
- 审查CRAB的流行病学和耐药性机制.
- 总结针对CRAB活性已批准药物的临床数据.
- 讨论CRAB感染的新兴和正在研究的疗法.
主要方法:
- 对流行病学数据的文献综述.
- 在CRAB中分析抵抗机制.
- 对CRAB疗法的临床试验数据的摘要.
- 讨论正在发展中的新型治疗方式.
主要成果:
- CRAB感染与高死亡率和有限的治疗选择有关.
- 现有的治疗方案显示出可变的疗效和安全性.
- 新兴的药物,如 cefiderocol 和 sulbactam-durlobactam 显示出潜力,但需要进一步验证.
- 几种新的治疗方案正在临床开发中取得进展.
结论:
- 为了有效管理CRAB,需要解决治疗异质性问题,并改善获得新疗法的机会.
- 临床验证和新药的可访问性对于打击全球CRAB威胁至关重要.
- 对新型治疗方法的持续研究对于改善CRAB感染的结果至关重要.
更多相关视频
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
07:41Author Spotlight: A Comprehensive Protocol for Acinetobacter Biofilm Quantification, Assessment, and Visualization
Published on: August 4, 2023
相关概念视频
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Development of Antibiotic Resistance
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Psychosis: Goals of Pharmacotherapy
